Rheumatoid arthritis (RA) is an inflammatory joint disorder that affects 0.5-1% of the population worldwide 1, 2 . Despite major advances in our understanding of RA pathogenesis, important unmet clinical needs remain for a large proportion of patients, whose disease is refractory to current treatments 3, 4 . Although autoantibodies have long been implicated in RA, it is now broadly accepted that environmental and epigenetic factors are also critical in the development and pathogenesis of joint disease 5 . Moreover, the aetiology of seronegative RA is not well understood 6 . An additional relatively under-recognized mechanism, altered lymphatic function, has the potential to modulate disease activity and the clinical course of RA via multiple pathways. Herein, we provide an overview of the synovial lymphatic system in the context of joint homeo stasis and inflammatory arthritis, review the experimental and clinical evidence that support the central importance of the lymphatic system in the progression and resolution of inflammatory arthritis, and introduce the concept that the lymphatic vasculature is a potential clinical diagnostic biomarker and novel therapeutic target in RA.
The lymphatic system Structure and function
In general, the peripheral lymphatic system has two primary functions: immune cell surveillance and interstitial fluid balance 7 . The lymphatic system maintains interstitial fluid balance by shifting fluid from the periphery through vessels that connect to a series of draining lymph nodes,which empty into final ducts (for example, the right lymphatic duct and thoracic duct) where the lymph is returned to the vascular supply via the subclavian veins 8 . Interstitial fluid becomes lymph when it enters the initial lymphatics or lymphatic capillaries that are present in most tissues, including the synovium (FIG. 1a) . These vessels are lined by a single layer of lymphatic endothelial cells (LECs) with specialized button-like junctions that are highly permeable to solutes and macro molecules, which physically attach to the extracellular matrix by anchoring filaments [9] [10] [11] [12] [13] [14] (FIG. 1b) . LECs overlap, creating primary valves that prevent the backflow of fluid into the tissue 12, 13 (FIG. 1c) . Entry of fluid into the lymphatic vessels takes place when external compressive forces are higher than the intraluminal fluid pressure, thereby
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pushing fluid, macromolecules and cells into the initial lymphatics 15, 16 . These external forces are generated by skeletal muscle contractions, ambulation or other joint movement.
The initial lymphatics converge to form larger collecting lymphatic vessels. These vessels are less permeable than the initial lymphatics owing to their tight zipper-like junctions between adjacent LECs 14 . In addition, collecting lymphatics contain secondary bicuspid valves, which help prevent backflow, and one or more layers of lymphatic muscle cells (LMCs), which allow for vessel contraction to move lymph against the force of gravity 9, 10, [17] [18] [19] (FIG. 1d) . LMCs have a myosin and actin cytoskeletal architecture with characteristics of both smooth muscle (SMA and SMB myosin heavy chain isoforms) and striated muscle (β-myosin heavy chain) 20 . Thus, these cells possess characteristics of both vascular smooth muscle and cardiac striated muscle, facilitating the generation of tone as well as strong, phasic contractions [20] [21] [22] . These contractile components respond to a tightly controlled cascade of signalling molecules that balances myosin light chain kinase, smooth muscle (MLCK) and myosin light chain phosphatase (a holoenzyme comprising three subunits: PP1c, a catalytic subunit of type 1 phosphatase; a target subunit, termed myosin phosphatase target subunit; and M20, a smaller subunit of unknown function 23 ) activity to produce the tone and contractile events (reviewed elsewhere 10 ). Briefly, contractions can be generated by stretchmediated, L-type or T-type calcium channels that generate an influx of Ca 2+ ions, which bind to calmodulin 24 . Calmodulin, in turn, activates MLCK, phosphorylating myosin light chain and shortening its length. LMCs are relaxed by nitric oxide (NO), which is synthesized by LECs and derived from various sources, including inducible nitric oxide synthase (iNOS), produced either directly or indirectly from immune cells travelling along the lumen of the vessel, and shear-stress-dependent activation of endothelial nitric oxide synthase (eNOS) 25 . NO translocates to the LMCs, where it activates soluble guanylyl cyclase and downstream cyclic GMP-dependent protein kinase (cGK-1, also known as protein kinase G), which blocks MLCK, enabling dephosphorylation of myosin light chain by its phosphatase and subsequent vessel relaxation 26 (FIG. 1e) .
Fluid courses through the lymphatic vessels until it enters a series of lymph nodes, which are highlyorganized organs containing immune cells and where adaptive immune responses are generated. Antigenic stimuli travel directly through the lymph, or are captured by antigen-presenting cells in the periphery and transported to the lymph nodes. Finally, lymph enters the sinuses via the afferent lymphatic vessel, exits in the efferent lymphatic vessel, and moves to the next lymph node, eventually returning to the circulation through the great veins. The pathways that lead to generation of an immune response are reviewed comprehensively elsewhere [27] [28] [29] [30] [31] and are beyond the scope of this Review. Whereas much is known about antigen transport and immune interactions in the peripheral lymph nodes, understanding of the specific processes that lead to lymph generation and lymphatic contraction in human joints is extremely limited, and studies that elucidate the synovial lymphatic system are at the forefront of this field.
Effects of inflammation on lymphatics
The lymphatic system and immune function are closely connected because antigen-presenting cells enter lymphatic vessels to travel to the lymph nodes where they initiate adaptive immune responses. Dendritic cells (DCs), neutrophils and macrophages travel through these vessels [32] [33] [34] [35] [36] . The importance of this lymphatic network is highlighted in mice lacking dermal lymphatics, which show decreased humoral immunity 37 . Interestingly, immune cells travelling adjacent to and within lymphatics can substantially alter the vessels by releasing factors that induce lymphangiogenesis and/or alter lymphatic vessel functions (such as contraction or permeability), and can also damage the vessel wall 38 . Lymphangiogenesis, or the growth of lymphatic vessels, is a primary response during inflammation, and disruption of this process leads to a variety of diseases 39 . Vascular endothelial growth factor C (VEGF-C), and its cognate receptor VEGF receptor 3 (VEGFR-3), expressed on LECs, are the master regulators of lymphangiogenesis 39 . Macrophages are a well-known source
• Dramatic changes in lymphatic vessel contraction and in the lymph nodes that drain inflamed joints are associated with disease progression and response to therapy in murine models of rheumatoid arthritis (RA) • During mild to moderate experimental arthritis, lymphatic vessels and nodes that drain the joint undergo an initial 'expansion' phase that facilitates efficient lymphatic clearance and lymphatic vessel contractions • In preclinical models, the expansion phase is followed by a 'collapsed' phase, in which B cells in the draining lymph node translocate from the follicles to lymphatic sinuses and the lymph node collapses • The collapsed phase is characterized by lymphatic vessel structural damage, loss of contraction, and reduction in lymphatic clearance • Pilot clinical studies indicate that alterations in lymph node volume and/or lymphatic flow could serve as biomarkers of treatment response with the potential to predict RA flare • Several lymphatic system-modulating therapies show promise in preclinical models of inflammatory arthritis and RA Figure 1 | Structure and function of the synovial lymphatic system. a | The synovial lymphatic system of arthrodial joints includes initial lymphatics interspersed throughout the synovium, which join to form collecting lymphatics that lead to joint-draining lymph nodes and, eventually, to the thoracic or right lymphatic duct, which joins the venous supply. of VEGF-C and are abundant in inflamed tissues 40, 41 . Importantly, activated macrophages and T cells cooperate to enhance expression of VEGF-C 42 . During inflammation, VEGFR-3 also regulates LEC expression of CC-chemokine 21 (CCL21), a potent chemotactic signal for DCs 32, 43 . These complex interactions reveal the presence of a coordinated system controlling lymphangiogenesis and immune cell migration.
Immune cell regulation of lymphatic contraction is facilitated primarily through cytokine-mediated NO signalling, as demonstrated by the reduced lymphatic contraction in a model of sterile inflammation; this reduced lymphatic contraction was not observed in iNOSknockout mice 44 . The reduction in lymphatic contraction frequency and ejection fraction was shown to be dependent on iNOS-expressing CD11b +
Gr1
+ cells that surround collecting lymphatic vessels 44 . Additionally, direct application of TNF and IL-1β in vivo can decrease lymphatic contraction frequency, which is mediated though iNOS 45 . This finding was confirmed in ex vivo studies in which lymphatic contraction was inhibited by direct application of TNF to mesenteric lymphatic vessels, and restored by antagonizing iNOS and guanylate cyclase 46 . The mechanism of this impairment is known to be partially dependent on arachidonic acid metabolites; the subject has been reviewed elsewhere 10, [47] [48] [49] . From ex vivo cannulation experiments, it is known that lymphatics respond to a variety of mechanical cues, including pressure, flow, and stretch [50] [51] [52] [53] . The increased fluid load traversing lymphatics during inflammation can increase all three of these factors. Contraction frequency increases in response to elevated transmural pressure, owing in part to increased shear that results in production of more NO 50, 52, 54, 55 . However, it should be noted that there seems to be a Gaussian relationship between pressure and flow, as contraction frequency reduces at high pressures 52 . When fluid load is lowered, and thus transmural pressure decreases, homeostatic contraction frequency returns. Therefore, whether a reduction in lymphatic contraction is mechanically and/or cytokine-mediated is difficult to determine from in vivo experiments.
Both initial and collecting lymphatics have an inherent permeability that is integral to their function. However, during inflammation, barrier integrity can be breached, leading to leakage of lymph into the interstitium. In the initial lymphatics, unidirectional flow facilitates the entry of fluid, cells, and macromolecules into the lymphatic system [9] [10] [11] [12] [13] [14] . During acute inflammation, permeability of the initial lymphatics increases, and tracer molecules flow back into the interstitium 56 . True measurements of initial lymphatic permeability are rare, but many groups have reported increased leakiness of the initial lymphatics in the presence of inflammation, which is a prospective sign of increased permeability [57] [58] [59] . Similarly, in a murine model of psoriasis, permeability increased in the initial dermal lymphatics of psoriatic plaques, but not in adjacent uninvolved skin 60 . In the collecting lymphatics, their inherent permeability is beneficial as it enables antigen sampling by macrophages and DCs in the surrounding adipose tissue, which facilitates downstream T cell responses 61 .
DCs regulate collecting lymphatic vessel permeability via CC-chemokine receptor 7 (CCR7)-dependent mechanisms 62 . Diabetic mice, and mice that have had a previous bacterial infection, also have increased collecting lymphatic permeability 63, 64 . Mechanistically, TNF and IL-1β can both increase LEC monolayer permeability in vitro 65, 66 . Thus, in contrast to the blood vasculature, permeability of lymphatic vessels is a highly regulated and dynamic process that changes during normal physiology and pathologic conditions.
Lymphatic phenotypes in RA
Evidence from mouse models Although several animal models of inflammatory erosive arthritis exist, none precisely recapitulates the pathophysiology of RA 67 . As such, they are broadly divided into models of autoimmunity, which are characterized by sudden onset of disease, and models of general joint inflammation, which display a more stochastic progression. K/B×N 68 and TNF transgenic (TNFtg) 69 mice are representative examples of these different RA models, respectively, and have distinct aetiologies of inflammatory erosive arthritis. Because joint pathogenesis is a dynamic process, one approach to study arthritic changes has focused on longitudinal imaging studies using contrast enhanced MRI (CE-MRI), power Doppler ultrasonography (PDUS), near-infrared indocyanine green (NIR-ICG) imaging, and in vivo micro-CT (μCT) 59, [70] [71] [72] [73] . With the use of these longitudinal imaging modalities, we found that K/B×N mice demonstrated a marked increase in lymphatic vessel contraction frequency during the acute phase of synovitis, which in the chronic phase of arthritis returns to levels similar to those seen in wild-type mice 59 . By contrast, the slow onset of inflammatory arthritis in TNFtg mice enabled us to identify that ankle and knee arthritis progresses by two distinct mechanisms, as illustrated in FIGURE 2. During the initial stages of arthritis and inflammation in the ankle joints of TNFtg mice, increased lymphangiogenesis maintains lymphatic drainage from the joint without a detectable increase in lymphatic vessel contractions compared with wild-type littermates (Supplementary information S1 (video)) 74 . This phase of arthritic progression is termed the 'expansion' phase because the popliteal lymph node enlarges in size owing to increased lymphangiogenesis, increased pressure from afferent vessels, and infiltration of IgM
hi B cells 59, [75] [76] [77] [78] [79] [80] [81] . Interestingly, this subset of B cells is distinct from marginal zone and follicular B cells in the lymph node, suggesting they are a unique population of B cells in inflamed lymph nodes, which we therefore named 'Bin' cells 79, 82 . The increase in lymphatic vessel contraction frequency in K/B×N mice, and lymphangiogenesis in both K/B×N and TNFtg mice, represent a compensatory response that enhances the removal of inflammatory cells and catabolic factors from the synovium. Functionally, this process limits joint inflammation and focal erosion in the expanding phase. In these models, however, this compensatory mechanism is incomplete because synovial inflammatory cells and catabolic factors directly damage LECs and LMCs when they pass through afferent lymphatic vessels and draining lymph nodes 83 . Following the expansion phase in the TNFtg model, the popliteal lymph node reduces in volume and power Doppler signal decreases, indicating reduced blood flow; these changes mark what has been termed the 'collapsed' phase of arthritic progression 70, 72 . This collapse coincides with several pathologic processes, including increased synovial hyperplasia, poor lymphatic clearance, lymphatic vessel damage with subsequent increased leakiness and loss of contractions (Supplementary information S2 (video)), leukocyte stasis within lymphatic vessels, translocation of Bin cells from the lymph node follicles to the lymph node sinuses, and reduction in draining lymph node volume with increased fluid pressure 70, [73] [74] [75] 79, 81 . Interestingly, the lymph node collapse is asymmetrical, and occurs along the ipsilateral axis of the lower limb 74 . Although a direct cause and effect relationship between the altered lymphatic dynamics outlined above and arthritic processes is not firmly established, the sequence of events fits with a unifying model to explain the collapsed phase (FIG. 2) . In this model, increased inflammatory cells, cytokines, chemokines and catabolic factors generated during persistent inflammation pass through the afferent lymphatic vessels, and damage LECs and underlying LMCs. Concomitantly, these catabolic factors trigger LECs to express high levels of iNOS, resulting in 'NO squelching' of eNOSmediated contractions. Thus, lymphatic vessel structural damage and NO production by LECs results in loss of lymphatic vessel contractions owing to constitutive activation of soluble guanylyl cyclase and downstream cGK-1-mediated inhibition of calcium signalling in LMCs (FIG. 1e) . At the same time, activated macrophages become static in the vessel lumen because of the loss of contractions. These cells also express iNOS, which furthers inhibition of lymphatic vessel contraction due to NO squelching. Additionally, activated macrophages in the draining lymph nodes express the potent B cell chemotactic factor CXC-chemokine 13 (CXCL13) 84 . A decrease or absence of lymphatic flow from afferent lymphatic vessels enables a CXCL13 gradient to form, increasing CXCL13 levels in the lymph node sinuses, which drives the migration of Bin cells from the follicles into the sinuses. As a result, these Bin cells accumulate and clog the lymphatic vessel. Both active and passive lymphatic transport from the inflamed joint is consequently markedly reduced or abolished, and is followed by progressive joint inflammation and destruction.
Lymph node collapse in RA Although lymph node involvement and lymphadenopathy in patients with RA was first described in 1896 by Chauffard and Ramond 85, 86 , follow-up studies have been hampered by the absence of reliable clinical outcome measures and biomarkers to assess lymphatic function, and to monitor disease progression and response to therapy. Knowledge of human lymphatics has advanced considerably in the past 10 years, based on recent pioneering studies using cadaveric dissection, which have mapped the lymphatic anatomy of the upper limb in detail 87, 88 . Moreover, clinical imaging strategies (CE-MRI, PDUS and NIR-ICG) [89] [90] [91] [92] [93] [94] [95] [96] have provided the first evidence that the lymphatics draining inflamed joints can serve as biomarkers of arthritis and response to therapy 93 . Additionally, ex vivo histopathology and immuno fluorescence analyses of popliteal lymph node tissues harvested from patients undergoing total knee replacement surgery or lower limb amputation have confirmed the presence of B follicular hyperplasia and histological alterations in lymph nodes, and the existence of Bin-like B cells, in tissue from patients with RA, findings not observed in tissues from patients with other (non-RA) severe lower limb diseases 80 . The next critical question is whether the phases of lymph node changes identified in murine studies are relevant to lymph node changes in RA. To address this question, Manzo and colleagues designed a proof-of-concept pilot study to formally examine whether RA is associated with alterations in the joint-draining lymph nodes 96 . Clinical and PDUS examination revealed hypertrophy of the lymph node cortex in the absence of clinical lymphadenopathy in seven out of ten patients with active disease, but there were no lymph node aberrations in the five patients in clinical remission or five healthy controls. Moreover, PDUS signal was amplified in the cortical and hilar regions of lymph nodes at baseline but returned to normal levels after 3 months of anti-TNF and/or methotrexate therapy 96 . In a follow-up study of 40 consecutive patients with RA refractory to treatment with DMARDs and 20 healthy individuals 95 , PDUS demonstrated considerable alterations of RA lymph node morphology and volume following anti-TNF treatment, and a degree of concordance of these alterations with synovitis activity in peripheral joints. Interestingly, low PDUS signal in the lymph nodes (which has also been observed in collapsed murine lymph nodes) 70, 72 at baseline was strongly associated with a poor clinical response to anti-TNF therapy. These studies provide initial evidence that lymph node dynamics, including changes in volume and PDUS signal, a marker of blood flow, are associated with joint pathology and responsiveness to treatment, and thus are a biomarker of RA disease activity and response to therapy.
Advances in RA flare assessment
The murine models outlined above demonstrate a strong temporal association between altered lymphatic flow and progressive joint inflammation and damage. A major question that emerges from these studies is whether the lymphatic dynamics contribute to joint inflammation in RA. Joint flare, a prevalent but poorly understood process in inflammatory arthritis, provides an opportunity to examine a potential relationship between the lymphatics and arthritis exacerbation.
In spite of aggressive treatment approaches based on combination therapies of conventional and biological DMARDs, one of the perplexing problems in RA care is the loss of response to therapies over time, and the well-recognized phenomenon of periods of episodic worsening of disease activity, often referred to as disease flare. Ongoing research has advanced our understanding of the descriptive characterization of flares from the perpsectives of patients and health care providers, yet we lack insight into the central pathophysiological correlates. Moreover, we lack the biomarkers of impending flare that are needed to facilitate early recognition and targeted intervention. As outlined in this Review, the discovery that altered lymph node dynamics and lymphatic flow precedes exacerbated arthritis in murine models provides critical clues to the existence of alternative pathways responsible for acute and chronic synovial inflammation, which might have relevance in patients with RA.
Inflammatory flares of RA are a well-recognized feature of the underlying disease. Some flares are self-limited, mild in nature, and resolve without intervention, whereas others persist and worsen, and ultimately represent the failure of a previously effective therapy and necessitate a change in treatment. Work ongoing over a number of years by multiple groups has sought to better characterize flares in RA. To facilitate research in the area, the Outcome Measures in Rheumatology Clinical Trials (OMERACT) group proposed to define the concept of RA flare as "worsening of signs and symptoms of sufficient intensity and duration to lead to change in therapy" (REFS 97, 98) , and further identified events that characterized flares along their continuum of severity 99 . This framework led to the development of a set of core domains to assess flare in RA, which included standard assessments of RA disease activity (swollen and tender joints, laboratory markers), patient and physician global assessments of disease activity, patient pain ratings, and assessment of physical function 100 . Additional assessments including fatigue, stiffness, and participation in life activities were subsequently added and validated [100] [101] [102] [103] . Demonstrating that patient reports and clinical assessments actually reflect events in the synovial microenvironment are important for linking clinical phenomenology with pathobiology. Ultrasonography and MRI have been used for such evaluations 93 . Ultrasonography is a powerful tool that provides point-of-care testing and objective evidence of active inflammation including the presence of joint effusions, synovial hypertrophy, and bone erosions 104, 105 . However, the utility of ultrasonography is limited by operator proficiency and the inability to visualize deeper anatomical structures 106, 107 . Compared with ultrasonography, MRI can image deep structures with high resolution, and therefore provide greater detail regarding disease activity, although its use is limited by cost, feasibility, and availability 107, 108 . Therefore, both imaging modalities are currently applied in a complementary fashion to evaluate arthritic disease.
Although limited in number, studies investigating the relationship between imaging outcomes and instruments assessing the OMERACT core domains have helped refine our understanding of the progression of RA flare. Applying the OMERACT definition of flare, Saleem and colleagues showed that some patients in clinical remission demonstrated power Doppler signals in the upper extremities (wrist and hand) that were predictive of subsequent flare 109 . Furthermore, in a cohort of patients with RA in clinical remission (n = 427), imaging of the hand, wrists and associated tendons by PDUS [110] [111] [112] detected tenosynovitis in 22.7% (95% CI 0.19-0.27), and these patients had an increased likelihood of flare as determined by the self-reported Flare Assessment in Rheumatoid Arthritis (FLARE) questionnaire (OR 1.95; 95% CI 1.17-3.26). These studies suggest that in clinically asymptomatic patients, ultrasonography (PDUS in particular) can reveal unstable or fluctuating inflammation that develops into flares.
MRI has also been used to evaluate synovial inflammation and its ability to assess or predict flare [113] [114] [115] [116] . Gaffney et al. used dynamic contrast-enhanced MRI (DCE-MRI), a method to assess 'wash in' and 'wash out' of contrast dye, to compare changes in knee synovial contrast enhancement to histological synovial changes via synovial biopsies in 20 patients with RA 114 . They found good correlation (r = 0.63, P <0.01) between histology and imaging. However, they were unable to correlate MRI synovial enhancement with flare as determined by clinical findings and use of the Health Assessment Questionnaire (HAQ, global assessment), or by the modified Ritchie Articular Index (local assessment). In a study performed in a cohort of patients with juvenile idiopathic arthritis, those who subsequently experienced a disease flare (12 of 32 patients), as defined by no longer meeting Wallace criteria for remission, had significantly different maximal enhancement of synovium on DCE-MRI at baseline compared with patients in remission over the course of the study (P = 0.05); a higher maximal enhancement was suggestive of flare potential 117 . The applicability of these findings to adults with RA requires confirmation, but this study suggests the potential usefulness of DCE-MRI for flare prediction.
Taken together, the efforts to define flare by use of questionnaires or imaging have provided valuable tools for diagnosis and possible intervention, yet the mechanisms that underlie this sudden alteration in joint inflammation remain enigmatic.
Lymphatic alterations in flare
The association between arthritic flare and lymph node dynamics is poorly understood. To explore this association, we performed a pilot clinical study to investigate the relationship between arthritic flare and popliteal lymph node volume by use of CE-MRI in 10 patients with RA, before and after anti-TNF therapy 90 . Knee flare in patients with chronic arthritis (disease duration >20 years) demonstrated advanced synovitis adjacent to focal bone erosions and small popliteal lymph nodes. In keeping with the findings in preclinical studies 75 , all patients with detectable lymph nodes on CE-MRI showed decreased lymph node volume after 16 weeks of anti-TNF therapy (mean decrease 37%; P = 0.002) 90 . Also, a significant improvement in knee pain was observed, as determined by the Rheumatoid and Arthritis Outcome Score 118 , which inversely correlated with a decrease in popliteal lymph node volume (r 2 = 0.94; P <0.05). In aggregate, these results suggest that patients with RA in whom draining lymph node volume is maintained during anti-TNF therapy experience the greatest amelioration of pain in flaring joints.
To formally establish quantitative biomarkers for draining lymphatics in RA, several human NIR-ICG imaging studies are ongoing. An example of this pioneering work comes from Sevick-Muraca and colleagues, who evaluated lymphatic vessels in patients with lymphoedema [119] [120] [121] . This group was the first to demonstrate lymphatic vessel contraction rates in healthy individuals 122 . An example of this experimental NIR-ICG imaging technology and its potential as a clinical diagnostic tool is presented in BOX 1 (see also Supplementary information S3 (video), Supplementary information S4 (video) and Supplementary information S5 (video)). Although no NIR-ICG imaging studies have been reported in patients with RA to date, open clinical protocols are actively enrolling participants 123 , and it is likely that data will be forthcoming in the next few years.
Lymphatic-modulating treatments for RA The findings in murine models of arthritis coupled with imaging findings in patients with RA strongly implicate the synovial lymphatic system in the events that promote exacerbation of arthritis. The next important challenge is to address therapeutic strategies to restore lymphatic flow (TABLE 1) . Therapeutic options -both FDAapproved RA therapies and novel lymphatic-modulating interventions -should be considered. It is fascinating to note that despite the efficacy of current targeted biologics, the mechanisms that promote resolution of synovitis remain enigmatic. Studies have focused on unique pathways that are interrupted by anti-TNF agents [124] [125] [126] and antibody-independent effects of anti-CD20 B cell depletion therapy 127, 128 . In particular, the marked reduction in synovial macrophage numbers following anti-TNF therapy does not result from apoptosis 129, 130 or altered
Box 1 | Near-infrared imaging of lymphatic vessels in humans
Visualization and quantification of lymphatic function with near-infrared (NIR) imaging provides a unique opportunity to examine the role of lymphatic contraction and flow in human disease 119, 120 . Following intradermal injections of a NIR dye, usually indocyanine green (ICG), images are captured by cameras sensitive to the NIR spectrum where ICG emits (peak of ~825 nm) to reveal lymphatic vessel anatomy and function. From cadaveric studies, we know that all areas of the dorsal hand drain through the major collecting vessels that initiate at the mid-dorsal aspect and cross the wrist, primarily running adjacent to the basilic or cephalic veins 87, 88, 169 . It is therefore likely that the metacarpal joints are also drained by these collecting vessels. Experimental NIR-ICG imaging (as described by Rahimi et al. 93 ) has been used for the analysis of human lymphatic flow in a study in which ICG was injected into the four web spaces of the hands of a healthy volunteer following informed consent 123 . a | In the NIR-ICG image on the left-hand side (a still image from Supplementary information S3 (video)), the major veins of the hand appear as dark vessels and lymphatic vessels (which fill with ICG) appear white. ICG signal is also apparent at the injection sites (*). The collecting lymphatic network is adjacent to the dorsal venous arch (arrowhead), and further joins together forming larger vessels adjacent to the basilic (dashed white arrow) and cephalic (solid white arrow) veins. b | Also shown is a schematic representation of these veins and lymphatic vessels. c | The graph (a still image from Supplementary information S3 (video)) quantifies lymphatic vessel contractions in the hand during a 10-minute imaging session, by plotting the signal intensity in a region of interest over time; spikes in signal intensity (white arrows) are scored as lymphatic contractions. Contraction frequency changes over time during inflammatory arthritis in mice 25, 38, 59, 73 , and could prove to be an important biomarker or outcome measure in human disease 44, 45, 83 . d | In the NIR-ICG image of the forearm from the same person in panel a (obtained in the same session as the hand image), the lymphatic vessels that drain the web spaces flank the cephalic and basilic veins across the mid-forearm and the antecubital fossa. e | Also shown is a schematic representation of these veins and lymphatic vessels. f | The graph (a still image from Supplementary information S5 (video)) presents quantification of the cephalic lymphatic vessel contraction frequency at the antecubital fossa, achieved through region of interest analysis.
Nature Reviews | Rheumatology . Rather, anti-TNF therapy restores lymphatic vessel contractions, attributed to lymphatic vessel repair and the restoration of contractions promotes leukocyte migration and egress from inflamed joints, as determined by transmission electron microscopy 83 . The pathways leading to joint inflammation and damage in the TNFtg murine arthritis model are lymphocyte-independent 132 , providing an ideal setting to assess the antibody-independent efficacy of B cell depletion 121 . With this in mind, the results of a study in which B cells were depleted in TNFtg mice before and after the onset of arthritis demonstrated that anti-CD20 prophylactic treatment prevented knee flare 79 , and therapeutic treatment of flaring mice with collapsed popliteal lymph nodes ameliorated inflammatory-erosive arthritis 73 . Moreover, longitudinal NIR-ICG imaging and immuno fluorescent intravital microscopy before and after anti-CD20 treatment demonstrated that B cell depletion restores passive lymphatic flow and leukocyte migration in lymphatic vessels without restoring contractions 73 . Given that anti-CD20 treatment removes Bin cells from the lymphatic sinuses in draining lymph nodes 73 , we conclude that B cell depletion maintains lymph node expansion by preventing Bin cell influx, and ameliorates arthritic flare by unclogging draining lymphatic vessels and restoring passive lymphatic flow. However, it should be noted that, although these B cells are polyclonal and do not seem to have the ability to express pro-inflammatory cytokines 79 , they can reduce inflammation or induce lymphangiogenesis by alternative mechanisms, as has been described elsewhere 133 .
Promoting lymphangiogenesis and drainage
Lymphangiogenesis is a compensatory response to joint inflammation, and inhibition of lymphatic vessel formation during arthritic progression considerably exacerbates disease 77 . Therefore, an intervention for RA that enhances lymphatic drainage from affected joints has therapeutic potential. An initial proof-of-concept study examining this potential found that injection of VEGF-C adeno-associated virus into inflamed murine joints reduced synovitis, bone erosion, cartilage loss and the number of infiltrating macrophages 134 . Interestingly, a 2014 study demonstrated that VEGF-C-VEGFR-3 signalling also inhibits macrophage activation via the regulation of the Toll-like receptor 4-nuclear factor-κB pathway 135 . Thus, VEGF-C might serve a dual therapeutic function in RA by improving lymphatic vessel function and inhibiting inflammation. Although gene therapies for arthritis have proven to have major clinical challenges 136 , it is of interest that a clinical trial of VEGF-C gene therapy for lymphoedema following mastectomy is currently ongoing 137 . Traditional Chinese medicines appeal to many patients, on the basis of their perceived safety and efficacy, coupled with the high costs and attendant risks associated with newer therapies. Indeed, traditional Chinese medicine is a mainstay therapy for arthritis worldwide 138 . To test if traditional Chinese medicines have direct effects on lymphatic dysfunction, TNFtg mice with established arthritis were treated with Du-Huo-Ji-Sheng-Tang (DHJST) 139 and its purified active compound ferulic acid 25 for 3 months. The treated mice showed reduced joint inflammation and bone and cartilage erosion 25 . Of particular relevance, DHJST and ferulic acid promoted lymphatic drainage from affected joints to draining lymph nodes while restoring lymphatic vessel contraction 25, 139 . Mechanistically, ferulic acid increased the expression levels of contraction-related genes in LMCs, and inhibited TNF-induced NO production by LECs 25 . DHJST and ferulic acid also increased lymphatic thoracic duct formation in zebrafish 139 . Another traditional Chinese medicine, Panax notoginseng, promoted LEC migration, tube formation, and VEGF-C expression 140 . Collectively, these findings suggest that traditional Chinese medicines regulate lymphatic vessel draining function by affecting LECs and LMCs, and might have DMARD activity.
Targeting lymphatic function
As described above, NO is a central regulator of lymphatic vessel contractions, and excessive iNOS-derived NO inhibits lymphatic vessel contractions in inflamed tissues (FIG. 1e) . Thus, there is a strong rationale for selective iNOS inhibition as a novel RA therapy. Indeed, a selective iNOS inhibitor (GW274150) was evaluated in a phase IIA clinical trial for early RA, and showed a trend towards reduction in synovial thickness (33%; P = 0.072) and synovial vascularity (42%; P = 0.075) compared with placebo at 28 days as shown by PDUS 141 . However, preclinical data suggest that expanding lymphatics predominate in early RA (FIG. 2) , and therefore that selective iNOS inhibition would have greater effects on advanced RA (collapsed phase), although this idea remains speculative. To test this hypothesis in TNFtg mice, we evaluated the effects of L-N6-(1-iminoethyl)lysine 5-tetrazole-amide (L-NIL), a moderately selective inhibitor of iNOS that does not affect eNOS activity 142 and reduces adjuvant-induced arthritis in rats 143 . Remarkably, we found that a single injection of L-NIL into the footpad of TNFtg mice with collapsed lymph nodes significantly increased dye uptake and restored lymphatic contractions within 300 s of administration, whereas injection of saline had no effect 25 . In another cohort of TNFtg mice, treatment with L-NIL, but not with saline or with the non specific NOS inhibitor Nω-nitro-l-arginine methyl ester (L-NAME), significantly increased lymphatic contraction in TNFtg mice, demonstrating that the recovery of lymphatic function was attributable to iNOS inhibition. Furthermore, no changes in lymphatic contractions were observed in wild-type mice treated with L-NIL, L-NAME or saline 25 . These proof-of-concept studies indicate that agents that selectively inhibit iNOS or iNOS-mediated downstream signals could represent new therapies for RA by regulating lymphatic vessel function.
Screening for lymphatic-modulating drugs using NIR-ICG imaging in wild-type mice revealed that a short-acting phosphodiesterase 5 (PDE5) inhibitor, sildenafil, induces lymphatic rerouting (Supplementary information S6 (video)) whereas placebo control does not (Supplementary information S7 (video)) (E.M.B, L.X., R.W.W., C.T.R. and E.M.S, unpublished data). This finding suggests a novel alternative intervention for collapsed lymphatics, in which dysfunctional lymphatic vessels can be circumvented by dilation of collateral lymphatic vessels; this approach warrants investigation in animal models of inflammatory arthritis. PDE5 in vascular smooth muscle cells hydrolyses cGMP and inhibits vessel relaxation. Therefore, we hypothesize that PDE5 inhibitors, such as sildenafil and tadalafil, promote LMC relaxation and could therefore reduce lymphatic contraction (FIG. 1e) . Future studies are necessary to validate these preliminary findings and confirm the mechanism of action of PDE5 in lymphatics.
Lymphatic drug targets in other disease states
The lymphatic system is now a major research focus owing to the central importance of lymphatic transit in homeostasis and evidence for its involvement in many disease processes, including Alzheimer disease, glaucoma, hypertension, myocardial infarction, lymphoedema, chronic bronchitis, and cancer [144] [145] [146] [147] [148] [149] . Although this research is still in its early stages, it has catalysed the need to understand basic lymphatic physiology (FIG. 1) and potential treatments targeting lymphatics.
Secondary lymphoedema is a prevalent conventional lymphatic disease, but effective therapies are not available. It often occurs when lymph nodes are removed during cancer therapy and can lead to impaired lymphatic transport. Therefore, treatments that increase lymphangiogenesis show promise. As mentioned above, VEGF-C gene therapy [150] [151] [152] [153] is being studied in a phase I clinical trial in patients with lymph node transplant and breast cancer-associated lymphoedema 137 . In a study published in 2017, bestatin, a leukotriene A4 hydrolase antagonist, alleviated experimental lymphoedema by improving lymphatic anatomy and promoting lymphangiogensis 154 ; this drug is currently under evaluation in a phase II clinical trial in patients with secondary lymphoedema of the lower limb 155 . Similarly, investigators have set out to improve lymphangiogenesis in other models with lymphatic insufficiencies. Treatment with VEGF-C reduced intraocular pressure and restored heart function after myocardial infarction in mouse models 145, 147 . Lymphangiogenesis can also be pathological. The cornea is avascular, but during cornea transplants there is often both angiogenesis and lymphangiogenesis, which is considered a poor prognostic factor 156 . In preclinical models, blocking lymphangiogenesis in a corneal graph improved the survival of the transplant 157, 158 . In this case, the regenerating lymphatics in cornea grafts deliver immune infiltrates that orchestrate graft rejection 159 .
It is now well-established that lymphatic dysfunction is an important factor in many disease states, and advances in imaging have allowed for the functional assessment of lymphatics, both preclinically and clinically. Preclinically, lymphatic contraction is inhibited in obesity 160 and inflammation 44 . Clinically, Dercum disease (adiposis dolorosa) 161 , chronic venous insufficiency 162 , and lymphoedema 163 demonstrate lymphatic contraction deficiencies. Moreover, in intestinal inflammation, a model of inflammatory bowel disease, lymphatic contraction can be restored with glibenclamide, which targets potassium channels located on LMCs 164 .
The preponderance of research is centered on understanding how lymphatics respond to a disease state or condition such as inflammation, whereas other investigations focus on how lymphatic dysfunction can drive disease. The most notable example of lymphatic dysfunction driving pathology and dysfunction is primary lymphoedema, which arises from a genetic mutation associated with loss of function in some component of the lymphatic vessel (such as the valves 165 or VEGFR-3 (REF. 166 )). However, preclinical work has shown that, at least in murine models, lymphatic malformations can lead to consequences other than lymphoedema. For instance, mice with haploinsufficiency in a gene essential for induction of the LEC phenotype (Prox1) were found to be a model for both lymphatic dysfunction and adult-onset obesity. Prox1 +/− mice have tortuous and leaky lymphatic vessels and manifest increased fat stores in lymphatic-rich regions; furthermore, lymph collected from Prox1 +/− mice promoted adipogenesis in vitro 167 . Similarly, Chy mice that are Vegfc haploinsufficient have lymphatic insufficiency, increased cutaneous fat deposition, chylous ascites and lymphoedema 168 .
Conclusions
Although lymphatics have long been recognized as important in the pathogenesis of inflammatory arthritis, this area of research has only in the past 10 years been enabled by longitudinal imaging, as described above. A high priority is investigation of the synovial lymphatic system, which originated from research aimed at elucidating the nature of the waxing and waning joint pathology characteristic of relapsing flare in RA 127, 128 . Mounting evidence demonstrates that lymphatic dysfunction exacerbates arthritic flare and disease progression in RA. Murine models have demonstrated that dramatic changes in lymphatic vessel function occur during the pathogenesis of inflammatory arthritis; these changes include an initial compensatory expanding phase in which the lymph node expands in size and lymphatic contraction and clearance are proficient, followed by a collapsed phase in which lymph nodes decrease in volume and there is a loss of the intrinsic lymphatic contraction. This dichotomy is mirrored by joint inflammation, where knee inflammation is not apparent until the collapsed phase, suggesting that targeting lymphatic function could be a potential treatment option and a promising area for future research.
Initial studies in patients demonstrate that alterations in the lymph nodes and lymphatic vessel function occur in RA. Moreover, NIR-ICG imaging can quantify lymphatic vessel function in patients, and permits identification of those who are likely to respond to specific treatments. Thus, we anticipate that therapies targeting lymphatic function will prove efficacious in RA.
